not-yet-known not-yet-known not-yet-known unknown Effectiveness of benznidazole in the treatment of Chagas disease in children and adults: a long-term retrospective cohort study
Bibliographic record
Abstract
not-yet-known not-yet-known not-yet-known unknown BACKGROUND: Chagas disease, caused by Trypanosoma cruzi, is endemic to the Americas but has spread worldwide due to migration. Benznidazole is effective, but long-term follow-up efficacy studies with benznidazole are few and they include only small numbers of patients. METHODS: We analyzed data from a retrospective cohort of Chagas disease patients treated with benznidazole at a large tertiary center in Argentina (1980–2019). Treatment response was assessed through clinical, parasitological, and serological follow-up. Parasitemia was evaluated by direct visualization or qPCR. RESULTS:A total of 567 benznidazole-treated patients were identified; 411 were children (median age: 46 months (IQR: 9.5 - 124 months) and 53 adults (median: 26 years, IQR 20 - 34 years) ). At diagnosis, 11/411 (2.68%) of children and 1/53 (1.9%) of adults were symptomatic, all of whom improved after treatment. Baseline parasitemia was detected in 289/445 (64.94%) of patients, and 279/289 (96.54%) had parasitological follow-up for at least three years. Benznidazole dosing was 6.6 mg/kg/day for children and 5.6 mg/kg/day for adults, with median treatment durations of 8 weeks and 31 days, respectively. All patients cleared parasitemia at the end of treatment. Median serological follow-up was 4.8 years for children (IQR: 22.4–111.5 months) and 2.8 years for adults (IQR: 10.3–67.9 months). At one-year follow-up, 38.8% of patients showed >20% reduction in T. cruzi antibody titers, and 29.8% achieved seronegativity, with younger patients converting faster (p < 0.01). CONCLUSIONS: In this Argentinian cohort, Benznidazole was highly effective, leading to sustained parasitemia clearance and declining antibody titers, supporting early treatment initiation.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.004 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".